Search Results

You are looking at 91 - 100 of 1,114 items for :

  • "breast cancer" x
  • Refine by Access: All x
Clear All
Full access

Brigette A. Davis, Jenerius A. Aminawung, Maysa M. Abu-Khalaf, Suzanne B. Evans, Kevin Su, Rajni Mehta, Shi-Yi Wang, and Cary P. Gross

Background Racial disparities are pervasive in medical care and are particularly well documented throughout the trajectory of breast cancer diagnosis and treatment. 1 , 2 Disparities in screening, follow-up, rates of referral, receipt of

Full access

Martin C. Mahoney

–2003 . National Cancer Institute , DCCPS, Surveillance Research Program, Cancer Statistics Branch. Available at : http://www.seer.cancer.gov . Accessed July 19, 2007 . 3. Singletary SE . Rating the risk factors for breast cancer . Ann Surg 2003

Full access

NCCN Guidelines® Insights: Breast Cancer, Version 4.2021

Featured Updates to the NCCN Guidelines

William J. Gradishar, Meena S. Moran, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Steven J. Isakoff, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, Marilyn Leitch, Janice Lyons, Jennifer Matro, Ingrid A. Mayer, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Kari B. Wisinski, Jessica S. Young, Jennifer L. Burns, and Rashmi Kumar

activity, participants will be able to: Integrate into professional practice the updates to the NCCN Guidelines for Breast Cancer Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Breast Cancer

Full access

William Gradishar and Kilian E. Salerno

Important “Tweaks” in Early-Stage Breast Cancer Guidelines Updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer were relatively minor, according to William Gradishar, MD, the Betsy Bramsen Professor

Full access

Margaret M. Kozak, Clare E. Jacobson, Rie von Eyben, Erqi L. Pollom, Melinda Telli, and Kathleen C. Horst

Each year, an estimated 14,000 women aged ≤40 years are diagnosed with breast cancer, which remains the leading cause of cancer-related death in this patient population. 1 Several studies have shown that breast cancer has more aggressive

Full access

Min Huang, Joyce O’Shaughnessy, Jing Zhao, Amin Haiderali, Javier Cortes, Scott Ramsey, Andrew Briggs, Vassiliki Karantza, Gursel Aktan, Cynthia Z. Qi, Chenyang Gu, Jipan Xie, Muhan Yuan, John Cook, Michael Untch, Peter Schmid, and Peter A. Fasching

Background Triple-negative breast cancer (TNBC) is a molecular subtype of breast cancer (BC) that lacks expression of the estrogen receptor, progesterone receptor, or HER2. 1 – 3 Research has shown that TNBC accounts for 10% to 20% of all patients

Full access

William J. Gradishar

“There are lots of endocrine agents for treating hormone-positive metastatic breast cancer. For relapsed/refractory disease, the data do not support that one sequence is better than the other,” revealed William J. Gradishar, MD, Betsy Bramsen

Full access

Caijin Lin, Jiayi Wu, Shuning Ding, Chihwan Goh, Lisa Andriani, Shuangshuang Lu, Kunwei Shen, and Li Zhu

Background Approximately 5% to 10% of patients with newly diagnosed breast cancer have distant metastases, with 5-year cancer-specific mortality (CSM) ranging from 60% to 74% among different races/ethnicities. 1 Median overall survival of patients

Full access

Sofia D. Merajver and Kara Milliron

National Cancer Data Base, 2000 . CA Cancer J Clin 2000 ; 50 : 171 – 183 . 3 Dupont WD Page DL . Risk factors for breast cancer in women with proliferative breast disease . N Engl J Med 1985 ; 312 : 146 – 151 . 4 Slattery ML

Full access

Richard L. Theriault

: 584 – 593 . 2 Giordano S Buzdar A Kau S-W . Improvement in breast cancer survival: Results from M. D. Anderson Cancer Center protocols from 1975-2000 (Abstr. #212) . Proc Am Soc Clin Oncol 2002 ; 21 : 54a . 3 Scheid V Buzdar